Australia's most trusted
source of pharma news
Tuesday, 21 July 2026
Posted 21 July 2026 PM
A Menarini’s Orfadin, previously only available under the Life Saving Drugs Program (LSDP) is the first medicine confirmed for PBS listing next month.
The hereditary tyrosinaemia type 1 treatment, which contains the active nitisinone has been available through the LSDP for just over 10 years. Orfadin was named as one of 17 potential August PBS contenders in a recent Pharma in Focus analysis.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.